W1789 The New Reflux Inhibitor Azd3355 Has a Low Propensity for Inducing Central Side Effects Due to Its Affinity for the GABA Carrier

Anders Lehmann(AstraZeneca (United Kingdom)), Sverker von Unge, Pirjo Saransaari, Jan P. Mattsson(Novartis (Switzerland)), Karolina Nilsson, Thomas Elebring(AstraZeneca (Sweden)), L. Ashley Blackshaw
Gastroenterology
April 1, 2008
Cited by 4


Related Papers